Wedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)The analyst comments "STRO ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche BankMay 14, 2024 4:12 PM Sutro Biopharma, Inc. (STRO) Misses Q1 EPS by 3cMay 13, 2024 5:19 PM Form 10-Q SUTRO BIOPHARMA, INC. For: Mar 31May 13, 2024 4:35 PM Form 8-K SUTRO BIOPHARMA, INC. For: May 13May 13, 2024 4:31 PM Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesMay 13, 2024 4:30 PM